AxoGen, Inc. Stock News
$31.70
0.99%
yesterday
Nasdaq,
Dec 18, 10:04 pm CET
Index
Industry
AxoGen, Inc. Stock News
Neutral
GlobeNewsWire
●
15 days ago
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Biologics License Application (“BLA”) for AVANCE® (acellular nerve allograft-arwx).
Positive
Reuters
●
15 days ago
The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.
Positive
Seeking Alpha
●
18 days ago
Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on Avance Nerve Graft, a pivotal regulatory inflection point. The BLA submission features over a decade of real-world outcomes, robust manufacturing validation, and clinical recovery rates in the low-...
Positive
Seeking Alpha
●
about one month ago
The strongest contributor to Wasatch Micro Cap Value Fund performance for the quarter was Bel Fuse, Inc. Axogen, Inc. (AXGN) was also a top contributor, providing surgical solutions for peripheral nerve repair. The greatest detractor from Fund performance for the quarter was Limbach Holdings, Inc. (LMB).
Neutral
Seeking Alpha
●
about 2 months ago
Axogen, Inc. ( AXGN ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Michael Dale - President, CEO & Director Lindsey Hartley - Chief Financial Officer Rick Ditto Jens Schroeder Kemp - Chief Marketing Officer Conference Call Participants Christopher Pasquale - Nephron Research LLC Michael Sarcone - Jefferies LLC, Research Division Caitlin Cronin - Canaccord Genuity Corp...
Neutral
GlobeNewsWire
●
about 2 months ago
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million
Neutral
Business Wire
●
3 months ago
LOS ANGELES--(BUSINESS WIRE)--Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN.
Neutral
Investors Business Daily
●
4 months ago
Shares of Axogen plunged Monday after the FDA delayed the expected approval date for the company's nerve graft product.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
